- Home
- GBX vs IMCR Comparison
GBX vs IMCR Comparison
Compare GBX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- IMCR
- Stock Information
- Founded
- GBX 1974
- IMCR 2008
- Country
- GBX United States
- IMCR United Kingdom
- Employees
- GBX N/A
- IMCR N/A
- Industry
- GBX Railroads
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBX Industrials
- IMCR Health Care
- Exchange
- GBX Nasdaq
- IMCR Nasdaq
- Market Cap
- GBX 1.8B
- IMCR 1.4B
- IPO Year
- GBX N/A
- IMCR 2021
- Fundamental
- Price
- GBX $42.86
- IMCR $28.41
- Analyst Decision
- GBX Hold
- IMCR Buy
- Analyst Count
- GBX 2
- IMCR 12
- Target Price
- GBX $57.00
- IMCR $60.90
- AVG Volume (30 Days)
- GBX 844.2K
- IMCR 403.7K
- Earning Date
- GBX 04-07-2025
- IMCR 05-07-2025
- Dividend Yield
- GBX 2.99%
- IMCR N/A
- EPS Growth
- GBX 85.75
- IMCR N/A
- EPS
- GBX 6.26
- IMCR N/A
- Revenue
- GBX $3,511,200,000.00
- IMCR $310,202,000.00
- Revenue This Year
- GBX N/A
- IMCR $20.52
- Revenue Next Year
- GBX $2.71
- IMCR $8.57
- P/E Ratio
- GBX $6.84
- IMCR N/A
- Revenue Growth
- GBX N/A
- IMCR 24.36
- 52 Week Low
- GBX $37.77
- IMCR $23.15
- 52 Week High
- GBX $71.06
- IMCR $62.74
- Technical
- Relative Strength Index (RSI)
- GBX 34.95
- IMCR 51.56
- Support Level
- GBX $39.02
- IMCR $26.37
- Resistance Level
- GBX $46.92
- IMCR $27.67
- Average True Range (ATR)
- GBX 2.64
- IMCR 1.76
- MACD
- GBX -0.19
- IMCR 0.10
- Stochastic Oscillator
- GBX 34.98
- IMCR 77.93
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.